COMBATTING MODERN SLAVERY AND HUMAN TRAFFICKING STATEMENT

This is the statement of Laboratory Corporation of America Holdings and subsidiaries Orchid Cellmark, Ltd., Bode Cellmark Forensics, Inc., Covance Limited, Covance Clinical and Periapproval Services Limited, Covance Clinical Research Unit Limited, Medaxial Limited, Covance Laboratories Limited, Fairfax Storage Limited, Chiltern International Group Limited and Chiltern International Limited (collectively “LabCorp”) for the financial year ending 31 December 2017 pursuant to section 54 of the UK Modern Slavery Act 2015. This statement has been approved by the boards of directors of those companies.

"LabCorp is committed to conducting business ethically, responsibly and with the utmost integrity. We are strongly committed to protecting human rights and eradicating modern slavery and human trafficking. We expect the same from all our business partners, including our suppliers and contractors. This statement describes the steps we have already taken and plan to take going forward to help prevent modern slavery and human trafficking in our supply chain and business. We intend to build on our policies and processes in the coming years as we work to deliver on our commitment and implement the steps described below."

- David P. King, Chairman and CEO, Laboratory Corporation of America Holdings

OUR BUSINESS, STRUCTURE AND SUPPLY CHAINS

LabCorp is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. The Company’s mission is to improve health and improve lives by delivering world-class diagnostic solutions, bringing innovative medicines to patients faster and using technology to provide better care. LabCorp serves a broad range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers (e.g. physician assistants and nurse practitioners), hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies and independent clinical laboratories. It reports operating results under two business segments, LabCorp Diagnostics and Covance Drug Development.

With net revenue of approximately $10 billion in 2017, LabCorp’s 57,000 employees serve hundreds of thousands of customers in approximately 60 countries, providing diagnostic, drug development and technology-enabled solutions for more than 110 million patient encounters per year.

LabCorp purchases equipment, laboratory supplies, pharmaceutical ingredients, components, and office supplies and furniture from third party suppliers, as well as services such as recruiting, staffing, facilities management, IT systems, recrdrds storage, courier and fleet among others.

Further details can be found at www.labcorp.com.
OUR POLICIES ON SLAVERY AND HUMAN TRAFFICKING

LabCorp will not tolerate human trafficking, forced labor, unlawful child labor, commercial sex acts or other unethical or illegal labor practices by our employees, agents and subcontractors or anywhere in our supply chain.

To reflect these commitments, LabCorp has adopted an enterprise-wide Ethical Labor and Anti-Human Trafficking Policy. The LabCorp Code of Conduct & Ethics and Supplier Code of Conduct also contain express prohibitions of any type of human trafficking, forced labor and unlawful child labor. LabCorp has also adopted a Compliance Plan for Combatting Human Trafficking under US Government Contracts, although it may be applied to other contracts and subcontracts where appropriate. We continue to review the Company’s existing policies and procedures to prevent modern slavery in contemplation of our particular risk.

The Corporate Compliance Department and Human Resources Department are responsible for monitoring compliance with the Ethical Labor and Anti-Human Trafficking Policy. LabCorp policies are consistently distributed throughout our business, to management at all levels and to our supply chains (as described below).

DUE DILIGENCE PROCESSES

LabCorp has put in place processes to:

- identify and assess potential risk areas in our business and supply chains;
- monitor potential risk areas in our business and supply chains;
- mitigate the risk of forced labor and trafficking occurring in our business and supply chains; and,
- protect whistle blowers.

LabCorp has adopted employment and recruitment standards and requirements to mitigate the risk of forced labor or trafficking. These are detailed in the Ethical Labor and Anti-Human Trafficking Policy and applicable Human Resources policies.

The Corporate Compliance Department has implemented a due diligence process for recruiting and staffing agencies, third-party call centers and other types of suppliers where a higher risk of forced labor and human trafficking could exist. This pre-contracting due diligence process includes reputational screening, review of applicable policies and support for wage rates.

STEPS TO ASSESS AND MANAGE RISKS

LabCorp has designated responsible departments to identify forced labor and trafficking risks and enhance or introduce appropriate measures to address those risks.
All subcontractors and suppliers are required to comply with the LabCorp Supplier Code of Conduct. All subcontractors and agents are notified of LabCorp’s Ethical Labor and Anti-Human Trafficking Policy and ethical labor and anti-human trafficking compliance provisions are incorporated into vendor contracts.

All employees are required to report any suspected forced labor, human trafficking or other activity inconsistent with LabCorp policies or applicable law. Employees may report activity, without fear of retaliation, either directly to managers or supervisors, the Corporate Compliance Department, the Law Department, the Chief Compliance Officer or through dedicated reporting lines set out in the LabCorp Action Line Policy. In addition to the internal LabCorp Action Line, LabCorp staff are also informed about and may use to report, without fear of retaliation, the US government’s global human trafficking hotline (1-844-888-FREE) and the UK government’s 24-hour modern slavery public telephone helpline (0800 0121 700).

TRAINING

To educate LabCorp staff to understand and be able to identify forced labor and trafficking risks in our supply chains and business, LabCorp has developed and provides appropriate training, with targeted training for personnel in human resources, procurement or with responsibility for supply chain management.

David P. King, Chairman and CEO
Director, Laboratory Corporation of America Holdings

F. Samuel Ebets III, Senior Vice President
Director, Bode Cellmark Forensics, Inc.
Director, Orchid Cellmark, Ltd.
Director, Chiltern International Group Limited
Director, Chiltern International Limited

Robert S. Pringle, Senior Vice President
Director, Covance Limited
Director, Covance Clinical and Periapproval Services Limited
Director, Covance Clinical Research Unit Limited
Director, Covance Laboratories Limited
Director, Medaxial Limited
Director, Fairfax Storage Limited

Date: April 2, 2018